You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
An innovative telomerase-targeted, circulating tumor cell assay for monitoring NSCLC treated with radiation and immunotherapy
SBC: Liquid Biotech USA, Inc. Topic: 102Project Summary: Cancer is a leading cause of death both in the United States and across the world, claiming over 600,000 and 8 million deaths each year, respectively. Delayed detection of cancer progression or recurrence after treatment contributes to increased morbidity and rapid death, but re-biopsy or repeat surgery is usually not possible due to severe risks. The accuracy of conventional imag ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a PCR assay for quantitative detection of HBV cccDNA
SBC: JBS SCIENCE INC Topic: NIAIDDevelopment of a PCR assay for quantitative detection of HBV cccDNA There is an urgent and unmet need for an effective method to detect hepatitis B virus (HBV) cccDNA in the blood. HBV infection affects nearly 350 million people worldwide. Chronic HBV infection is a major risk factor for the development of severe liver diseases such as cirrhosis and hepatocellular carcinoma, which has a poor survi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Post-surgical Incision Management Device to Prevent Ostomy Complications
SBC: FISTULA SOLUTION CORPORATION Topic: 102Project Summary/Abstract Over 100,000 patients of all ages undergo ostomy surgery in the United States (US) annually due to a variety of pathophysiologic conditions including colorectal cancer, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), bowel obstruction, diverticulitis, and many other medical conditions. Ostomy surgery may also be necessary in cases of severe abdominal ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation
SBC: Advent Therapeutics, Inc. Topic: NHLBIAdvent Therapeutics (Advent) is a biotech focusing on novel approaches to reformulate and optimize delivery of legacy drugs with proven efficacy to address unmet medical needs of specific underserved and orphan patient populations. Advent is developing an aerosol formulation of its proprietary, optimized water miscible vitamin A (vitA) palmitate for non-invasive (inhaled) delivery to preterm infan ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIAIDAbstract. Chagas disease is a neglected tropical disease and has been designated as a research priority by NIAID and an SBIR Research Topic of Interest. Six million individuals are infected and 8,000 deaths were caused by Chagas in 2015 in mostly Central and South America by advanced forms of the disease such as Chagas hemorrhagic fever. The cost associated with Chagas disease treatment globally i ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of BIO 300 as a novel treatment for idiopathic pulmonary fibrosis
SBC: HUMANETICS CORP Topic: NHLBIProject Summary Idiopathic pulmonary fibrosis (IPF) is a serious lung disease characterized by progressive scarring of the tissue in the lungs. IPF is associated with a particularly poor prognosis with most patients succumbing to the disease within 3-5 years from the time of diagnosis. Two antifibrotic therapies, nintedanib and pirfenidone, have been approved in recent years for the treatment for ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis
SBC: PRENOSIS INC Topic: 300Principal Investigator/Program Director (Last, first, middle): Reddy, Jr., Bobby Project Summary: Sepsis is a poorly understood clinical syndrome characterized by dysregulated host response to infection. The complexity and heterogeneity of the host response has frustrated attempts at developing effective treatments. In partnership with 6 U.S. hospitals, Prenosis amassed NOSIS, one of the world’s ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A single antiviral to treat multiple opportunistic infections
SBC: EVRYS BIO LLC Topic: NIAIDPROJECT SUMMARY/ABSTRACT Immunosuppressed transplant patients have heightened susceptibility to environmental pathogens as well as adventitious agents traveling with donor tissues or resident in the recipient. Traditional therapies target the virus and are thereby limited in effectiveness to the specific virus targeted. Evrys Bio is developing orally administered, broad-spectrum antivirals that ta ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Stop pulmonary airleaks with a novel inhaled dry powder aerosol
SBC: Quench Medical Inc. Topic: NHLBIProject Summary AbstractOver 30,000 Americans suffer each year from pulmonary airleaks leading to collapsed lungs with painful, invasive treatments, and costly hospitalizations. Current treatments are not effective enough in controlling airleaks and medical providers are seeking new therapies. There is strong evidence that a locally delivered therapeutic via inhalation would have a major impact on ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of A Novel Nanoparticle Biosensor for Rapid, Point-of-Care Sepsis Diagnosis and Risk Assessment
SBC: NAMI DIAGNOSTICS LLC Topic: NIAIDAbstract. In the United States, about 1.7 million adults affected by sepsis annually, which leads to more than 270,000 deaths per year. If sepsis cannot be diagnosed and treated early, it not only causes high morbidity and mortality rates, but also poses a major burden to the healthcare system since septic patients are generally hospitalized for extended stay and rarely discharged from ICU before ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health